Optimal EGFR TKIs Treatment Strategies for Lung Adenocarcinoma Harboring EGFR Exon 19 Deletion Variants
NCT04370860 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1000
Last updated 2022-08-17
Summary
To determine the optimal EGFR TKIs treatment strategies for lung adenocarcinoma harboring EGFR exon 19 deletion variants
Conditions
- EGFR Exon 19 Mutation
- Tumor Progression
Sponsors & Collaborators
-
National Taiwan University Hospital
lead OTHER
Eligibility
- Min Age
- 20 Years
- Max Age
- 90 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-05-01
- Primary Completion
- 2021-12-31
- Completion
- 2021-12-31
Countries
- Taiwan
Study Locations
More Related Trials
-
Primary Tumor Resection Plus Osimertinib in Advanced EGFR-mutant Non-small Cell Lung Cancer
NCT07177092 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Real-world Treatment Patterns and Clinical Outcomes in EGFR-mutant Unresectable Locally Advanced NSCLC
NCT04304638 ·Status: UNKNOWN
-
Weekly Use First-generation EGFR-TKI in the Treatment of EGFR-TKI Acquired Resistance Non-small Cell Lung Cancer (NSCLC)
NCT02575560 ·Status: COMPLETED
-
Primary Tumor Resection With EGFR TKI for Stage IV NSCLC
NCT05215548 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Erlotinib Versus Gemcitabine/Carboplatin in Chemo-naive Stage IIIB/IV Non-Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Exon 19 or 21 Mutation
NCT00874419 ·Status: COMPLETED ·Phase: PHASE3
-
EGFR-TKIs Combine Chemotherapy as First-line Therapy for Patients With Advanced EGFR Mutation-positive NSCLC
NCT02886195 ·Status: UNKNOWN ·Phase: PHASE3
-
Efficacy of EGFR TKIs in Patients With Rare EGFR-mutated NSCLC
NCT01775943 ·Status: UNKNOWN
-
Epidermal Growth Factor Receptor (EGFR) T790M Mutation Testing Practices in Hong Kong
NCT03519958 ·Status: WITHDRAWN
-
Epidermal Growth Factor Receptor Mutations in the Blood of Patients With Advanced Non-Small Cell Lung Cancer
NCT00899756 ·Status: COMPLETED
-
Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC
NCT04324164 ·Status: RECRUITING
-
Multicentre Study to Explore the Correlation Between Smoking Pattern and Clinical Efficacy of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) in Male Patients
NCT00922025 ·Status: COMPLETED
-
Impact of Concomitant Genetic Alterations in EGFR Mutated Adenocarcinoma by NGS Analysis: A Multicenter Study
NCT04122833 ·Status: UNKNOWN
-
A Spanish Medical Record Review of Clinical Characteristics and Outcomes in Non-small Cell Lung Cancer Participants With EGFR Exon 20 Insertion
NCT05419700 ·Status: COMPLETED
-
A Retrospective EGFR Mutation Status Study in Chinese NSCLC Patients Using Paired Plasma and Tissue Samples
NCT01382992 ·Status: UNKNOWN
-
De Novo Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors
NCT01697163 ·Status: UNKNOWN
-
Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis
NCT01776684 ·Status: UNKNOWN ·Phase: NA
-
A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment
NCT01994057 ·Status: RECRUITING
-
A Non-interventional Survey on the EGFR (Epidermal Growth Factor Receptor) Mutation Status in Completely Resected Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Adenocarcinoma Histology
NCT01106781 ·Status: COMPLETED
-
Efficacy of Osimertinib in Patients With Lung Cancer
NCT06174857 ·Status: RECRUITING
-
A Multicenter Prospective Study to Assess the Effects of Adjuvant Icotinib in EGFRm Stage I NSCLC With High-risk of Disease Recurrence After Complete Resection
NCT05514314 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study to Predict Gefitinib' s Efficacy for Lung Cancer by Plasma Free Nucleic Acids EGFR Gene Mutation Test
NCT02738684 ·Status: UNKNOWN
-
PRe-Operative Gefitinib in Resectable EGFR Mutation Positive Lung Cancer With Sector Sequencing for Biomarker Discovery
NCT02804776 ·Status: COMPLETED ·Phase: PHASE2
-
Assessing an Oral EGFR Inhibitor,YK-209A in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR
NCT05767866 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Acquired Resistant Mechanism of the First-generation EGFR TKIs
NCT02804217 ·Status: UNKNOWN
-
Adjuvant Treatment Based on MRD for EGFR Mutant NSCLC
NCT05536505 ·Status: RECRUITING ·Phase: PHASE2